Selumetinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Healthy Volunteers Pharmacokinetic Study
Conditions
Healthy Volunteers Pharmacokinetic Study
Trial Timeline
Oct 1, 2013 → May 1, 2014
NCT ID
NCT01960374About Selumetinib
Selumetinib is a phase 1 stage product being developed by AstraZeneca for Healthy Volunteers Pharmacokinetic Study. The current trial status is completed. This product is registered under clinical trial identifier NCT01960374. Target conditions include Healthy Volunteers Pharmacokinetic Study.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03259633 | Pre-clinical | Completed |
| NCT04924608 | Phase 3 | Active |
| NCT05101148 | Phase 1 | Active |
| NCT04590235 | Phase 1 | Active |
| NCT04495127 | Phase 1 | Completed |
| NCT03326388 | Phase 1/2 | Completed |
| NCT03095248 | Phase 2 | Terminated |
| NCT02063204 | Phase 1 | Completed |
| NCT01960374 | Phase 1 | Completed |
| NCT01752569 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Healthy Volunteers Pharmacokinetic Study
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 33 |
| Valsartan | Novartis | Phase 1 | 33 |
| CSL112 + Placebo | CSL | Phase 1 | 32 |
| UT-15C | United Therapeutics | Phase 1 | 30 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 25 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 25 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 25 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 25 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 25 |
| TRV734 | Trevena | Phase 1 | 25 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 33 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 28 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 33 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 23 |
| LY2157299 | Eli Lilly | Phase 1 | 33 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 33 |
| LOXO-783 | Eli Lilly | Phase 1 | 33 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 33 |